Meglutol API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Meglutol is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Meglutol or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Meglutol API 503-49-1?

Description:
Here you will find a list of producers, manufacturers and distributors of Meglutol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Meglutol 
Synonyms:
3-hydroxy-3-methylglutaric acid , Dicrotalic acid , Meglutol  
Cas Number:
503-49-1 
DrugBank number:
DB04377 
Unique Ingredient Identifier:
CLA99KCD53

General Description:

Meglutol, identified by CAS number 503-49-1, is a notable compound with significant therapeutic applications. An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate limiting enzyme in the biosynthesis of cholesterol.

Classification:

Meglutol belongs to the class of organic compounds known as hydroxy fatty acids. These are fatty acids in which the chain bears a hydroxyl group, classified under the direct parent group Hydroxy fatty acids. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Fatty Acyls class, specifically within the Fatty acids and conjugates subclass.

Categories:

Meglutol is categorized under the following therapeutic classes: Acids, Acyclic, Anticholesteremic Agents, Antimetabolites, Dicarboxylic Acids, Enzyme Inhibitors, Glutarates, Hypolipidemic Agents, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Meglutol is a type of Antimetabolites


Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.

One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.

Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.

Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.

In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.